The differential expression of the target single gene in normal brain, low-grade glioma, and high-grade glioma tissues was verified by immunohistochemical experiments. This experiment was approved by the Ethics Committee of the First Hospital of Shanxi Medical University and complied with the Declaration of Helsinki. Five normal brain tissues were collected from patients with traumatic brain injury or epilepsy, 10 postoperative tissues from patients with low-grade glioma, and 10 postoperative tissues from patients with high-grade glioma. After routine paraffin embedding, tissue sections were taken, placed on slides, deparaffinized, and rehydrated. After antigen retrieval and endogenous peroxidase blockade, they were then exposed to monogenic polyclonal antibodies (bs-13168R, Bioss) and enzyme-labeled IgG polymers. Diaminobenzidine (DAB) chromogenic solution and hematoxylin were used as a counterstain to visualize the presence of antibodies. Immunohistochemical image analysis was performed using the Scanscope digital pathology scanning system from Aperio, USA, and the expression of FCGBP in tissues was quantified by Cytoplasmic V2 software with Cytoplasm H-Score. Cytoplasm H-Score was obtained by multiplying the percentage of positive cells by the staining intensity score.